Market News AIOpen the app

Agilent has introduced the SureSelect Cancer Research Pan Heme, a new tool for studying blood cancers.

ProductRead the original at biospectrumasia.com
Good for A

Agilent launched a test that combines DNA and RNA profiling, sample preparation, and analysis software, expanding its cancer research lineup. No sales or customer uptake figures were reported, so the business benefit is not yet proven.

A · Agilent Technologies, Inc.

AI read · Good for A

The AI's read

The combined DNA and RNA workflow gives research labs one system for sample preparation and data analysis. It also works with Agilent's automated preparation system and adds to its tools for solid tumors. The story reports no sales or customer uptake, so the benefit is a new option, not proven business growth.

Get alerts for A

Follow Agilent Technologies, Inc. (A) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for A
Free on the App Store and Google Play, or on the web.